Last Updated: Apr 30, 2016
- Elevated integrin ?6?4 expression is associated with venous invasion and decreased overall survival in non-small cell lung cancer.
Stewart Rachel L, et al. Human pathology 2016 4 - The Frequency of EGFR Mutation in Lung Adenocarcinoma and the Efficacy of Tyrosine Kinase Inhibitor Therapy in a Hungarian Cohort of Patients.
Sárosi Veronika, et al. Pathology oncology research : POR 2016 4 - Detection of EML4-ALK fusion gene and features associated with EGFR mutations in Chinese patients with non-small-cell lung cancer.
Wen Miaomiao, et al. OncoTargets and therapy 2016 0 1989-95 - Associations between FAS rs2234767 and FASL rs763110 polymorphisms and the risk of lung cancer: a meta-analysis of 39,736 subjects.
Yu Xiongjie, et al. OncoTargets and therapy 2016 0 2049-56 - Clinical efficacy of erlotinib, a salvage treatment for non-small cell lung cancer patients following gefitinib failure.
Cho Kyoung Min, et al. The Korean journal of internal medicine 2016 4 - Lifestyle factors and contact to general practice with respiratory alarm symptoms-a population-based study.
Sele Lisa Maria Falk, et al. BMC family practice 2016 0 (1) 47 - 2-Phenethyl isothiocyanate, glutathione S-transferase M1 and T1 polymorphisms, and detoxification of volatile organic carcinogens and toxicants in tobacco smoke.
Yuan Jian-Min, et al. Cancer prevention research (Philadelphia, Pa.) 2016 4 - Epidermal growth factor receptor mutation and pattern of brain metastasis in patients with non-small cell lung cancer.
Baek Min Young, et al. The Korean journal of internal medicine 2016 4 - Efficacy of Pemetrexed-based Chemotherapy in Patients with ROS1 Fusion-positive Lung Adenocarcinoma Compared with Patients Harboring Other Driver Mutations in East Asian Populations.
Chen Yen-Fu, et al. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2016 4 - Determinants of Gefitinib toxicity in advanced non-small cell lung cancer (NSCLC): a pharmacogenomic study of metabolic enzymes and transporters.
Ma Y, et al. The pharmacogenomics journal 2016 4 - Association of CYP1A1, GSTM1 and GSTT1 gene polymorphisms with risk of non-small cell lung cancer in Andhra Pradesh region of South India.
Peddireddy Vidyullatha, et al. European journal of medical research 2016 0 (1) 17 - Genomic Landscape Survey Identifies SRSF1 as a Key Oncodriver in Small Cell Lung Cancer.
Jiang Liyan, et al. PLoS genetics 2016 4 (4) e1005895 - Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial.
Planchard David, et al. The Lancet. Oncology 2016 4 - Morphological and molecular approach to synchronous non-small cell lung carcinomas: impact on staging.
Schneider Frank, et al. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2016 4 - Circulating cell-free DNA has a high degree of specificity to detect exon 19 deletions and the single-point substitution mutation L858R in non-small cell lung cancer.
Qian Xin, et al. Oncotarget 2016 4 - Different effects of the three polymorphisms on 15q25.1 onlung cancer risk: Evidence from published literatures.
Sun Huiling, et al. Journal of cancer research and therapeutics 0 0 (1) 12-9 - Serum carcinoembryonic antigen levels predicts the efficacy of EGFR-TKI in non-small cell lung cancer harboring EGFR mutations.
Yanwei Zhang, et al. Journal of cancer research and therapeutics 0 0 (1) 254-8 - Prognostic factors in patients with brain metastasis from non-small cell lung cancer treated with whole-brain radiotherapy.
Harada Hideyuki, et al. Journal of cancer research and therapeutics 0 0 (1) 267-70 - Epidermal growth factor receptor mutations and brain metastasis in patients with nonadenocarcinoma of the lung.
Shin Dong-Yeop, et al. Journal of cancer research and therapeutics 0 0 (1) 318-22 - Predictive and prognostic value of preoperative serum tumor markers is EGFR mutation-specific in resectable non-small-cell lung cancer.
Jiang Richeng, et al. Oncotarget 2016 4 - EGFR, ALK, RET, KRAS and BRAF alterations in never-smokers with non-small cell lung cancer.
Dong Y U, et al. Oncology letters 2016 4 (4) 2371-2378 - A sensitive and practical method to detect the T790M mutation in the epidermal growth factor receptor.
Zhao Jing, et al. Oncology letters 2016 4 (4) 2573-2579 - High body mass index and cancer risk-a Mendelian randomisation study.
Benn Marianne, et al. European journal of epidemiology 2016 4 - Pretreatment albumin-to-globulin ratio as a predictive marker for tyrosine kinase inhibitor in non-small cell lung cancer.
Park Sehhoon, et al. Cancer biomarkers : section A of Disease markers 2016 3 (3) 425-33 - Association of Single Nucleotide Polymorphisms in the Apoptosis-Related Genes TP63 and CD40 with Risk for Lung Cancer in a Chinese Han Population.
Tang WenJun, et al. The Tohoku journal of experimental medicine 2016 0 (4) 279-86 - Epidemiology of Lung Cancer in Korea: Recent Trends.
Park Ji Young, et al. Tuberculosis and respiratory diseases 2016 4 (2) 58-69 - Combinations of the Variant Genotypes of CYP1A1, GSTM1 and GSTT1 are Associated with an Increased Lung Cancer Risk in North Indian Population: a Case-Control Study.
Girdhar Yashila, et al. Pathology oncology research : POR 2016 4 - Prospective Validation of Rapid Plasma Genotyping for the Detection of EGFR and KRAS Mutations in Advanced Lung Cancer.
Sacher Adrian G et al. JAMA oncology 2016 Apr - A Significant Statistical Advancement on the Predictive Values of ERCC1 Polymorphisms for Clinical Outcomes of Platinum-Based Chemotherapy in Non-Small Cell Lung Cancer: An Updated Meta-Analysis.
Han Yali, et al. Disease markers 2016 0 7643981 - Genetic variants of CHRNA5-A3 and CHRNB3-A6 predict survival of patients with advanced non-small cell lung cancer.
Wang Yang, et al. Oncotarget 2016 3
- Human (3751)
- Pathogen (0)
- Human (53)
- Pathogen (0)
No hay comentarios:
Publicar un comentario